Genmab A/S FY2025 EPS Estimate Increased by William Blair

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Equities researchers at William Blair raised their FY2025 earnings per share estimates for Genmab A/S in a research note issued on Monday, July 14th. William Blair analyst M. Phipps now forecasts that the company will post earnings per share of $1.62 for the year, up from their previous estimate of $1.61. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share.

Several other equities research analysts have also recently commented on GMAB. Wall Street Zen raised Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday. Sanford C. Bernstein cut Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday, April 1st. HC Wainwright reissued a “buy” rating and set a $37.00 target price (down previously from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Finally, Truist Financial raised their target price on Genmab A/S from $45.00 to $46.00 and gave the stock a “buy” rating in a research note on Tuesday, July 8th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $37.80.

Genmab A/S Stock Performance

NASDAQ:GMAB opened at $21.15 on Tuesday. Genmab A/S has a one year low of $17.24 and a one year high of $28.56. The stock has a market cap of $13.57 billion, a PE ratio of 12.02, a P/E/G ratio of 6.52 and a beta of 0.94. The stock has a 50 day moving average price of $21.05 and a 200 day moving average price of $20.75.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The firm had revenue of $715.00 million during the quarter, compared to analysts’ expectations of $5.17 billion.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of GMAB. EverSource Wealth Advisors LLC boosted its position in shares of Genmab A/S by 295.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares during the period. Headlands Technologies LLC boosted its position in shares of Genmab A/S by 1,525.0% during the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company’s stock worth $31,000 after buying an additional 1,464 shares during the period. Caitong International Asset Management Co. Ltd boosted its position in shares of Genmab A/S by 124.3% during the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company’s stock worth $38,000 after buying an additional 1,070 shares during the period. Barclays PLC boosted its position in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after buying an additional 2,285 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Genmab A/S during the fourth quarter worth $60,000. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.